This phase II clinical trial is studying how well response-based therapy assessed by PET scan works in treating patients with bulky stage I and stage II Hodgkin lymphoma. PET scans will be obtained during the course of therapy. Researchers will evaluate the usefulness of this PET scan to determine whether radiation may be left out in the treatment of disease if the PET scan shows a response to chemotherapy alone. In addition, a small percentage of patients may have disease that is not adequately treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy. Researchers hope to identify this group of patients using early PET scans and will change to a chemotherapy treatment called BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in decreasing craving in individuals who habitually smoke cigarettes. The study consists of six total visits to MUSC; one for the consent process, two that will include MRI scans, and five that will include TMS administration. Compensation will be provided for each visit.
This study will evaluate the safety of VX-661 in combination with ivacaftor over 3 months in subjects with Cystic Fibroisis 12-years-old and older who are heterozygous for the F508del mutation and a second CFTR Allele.This study has 2 treatment periods: an Ivacaftor Run-in Period for 4 weeks, followed by a treatment period for 8 weeks.
The purpose of this study is to develop repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for opiate dependence addiction. Repetitive TMS is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether rTMS over the prefrontal cortex can produce a reduction in your perception of pain, your desire to use opiates, and your brain?s response to opiate cues. TMS has been approved by the FDA as an investigational tool as well a therapy for depression.
Major depressive disorder (MDD) is a mental illness in which affected individuals have low mood with low self-esteem, and loss of interest or pleasure in normally enjoyable activities. It is a long-term illness for many subjects and maintenance therapy is recommended to prevent relapse in subjects with recurrent depression.
The purpose of this study is to test the efficacy and safety of doses of vortioxetine capsules (5, 10 or 20 mg/day) compared with placebo (a non-active capsule/ ?dummy drug?) in preventing relapse in people with acute recurrent MDD.
People with Cystic Fibrosis (CF) often have thick mucus in the airways of the lungs that is hard to cough up. The mucus can build up and eventually lead to a chronic cough. The mucus is also a good environment for bacteria (germs) to live and grow, rapidly leading to infections. One bacteria, Pseudomonas aeruginosa (Pa) is particularly good at living in the CF lung. People with CF who agree to take part in this study would be those who have had Pa in their lungs for at least 1 year.
The purpose of this research study is to test the effect of an infusion (through a vein) of a drug called gallium nitrate in patients with CF. Laboratory tests suggest that this drug may be able to fight Pa infections. Gallium nitrate is an FDA approved drug that is used to treat high calcium in the blood caused by cancer. The drug also works in other bone diseases and has been used to treat certain cancers.
If the study shows that the drug is safe and may be helpful in treating CF, additional studies with gallium nitrate may be done in patients with CF in the future.
The primary objective of the study is to assess the safety of Belimumab following treatment with Rituximab and Cyclophosphamide in patients with Lupus Nephritis. The study will last for about 2 years and will involve 20 study visits. Patients who meet criteria will be assigned to one of two groups: Group 1 will have Rituximab plus Cyclophosphamide followed by Belimumab infusions, and Group 2 will have Rituximab plus Cyclophosphamide, but will not have the Belimumab infusions. This study is not blinded, so patients will know what group they are assigned to. Patients will be followed closely by the study doctors to determine their lupus activity levels over the course of 2 years.
Systemic sclerosis (SSc) or scleroderma is an autoimmune disease in which a person?s own immune cells attack his/her skin and internal organs, including the joints, lungs, heart, intestinal tract, and kidneys. The effects on the lungs, including pulmonary arterial hypertension (PAH), are among the most serious complications of SSc. In general, PAH is defined as an increase in pressure in the pulmonary arteries (the main blood vessels that lead from the heart to the lungs). Treatments for PAH have focused on symptom management rather than curing the disease.
This study has been designed to look at a new approach to treating the cause of the disease, rather than the symptoms of the disease. Recent research suggests that SSc-PAH may be the result of an ?attack? by immune cells. This study will look at the effect of the drug rituximab on the immune system and the immune ?attack? on the lungs. Rituximab is an immunosuppressive drug that eliminates the B cells for a few months, and therefore may halt the B cell attack on the lungs thought to be associated with this disease.The recovery of your B cells will be closely monitored throughout the study by blood testing.
Social stress often leads to drug craving and relapse in cocaine-dependent populations. Currently there are no FDA approved medications for the treatment of cocaine dependence. Therefore, biomedical research studies aimed at investigating the brain mechanisms responsible for controlling emotional responses to social stress could have a significant impact on the development of effective therapeutic treatment strategies for cocaine-dependent individuals.
This study is for individuals with renal cell carcinoma (RCC). The purpose of this study is:
?To find out whether the study treatment can stop your RCC from growing, or prevent it from growing as fast as it would without dalantercept.
?To evaluate the safety of the study treatment in subjects with RCC.
?To find out if the study treatment has an effect on biomarkers (molecules that indicate how well you respond to study treatment) in your blood and/or tissue.
Participants will receive a dose of dalantercept or placebo (a substance with inactive drug that looks the same as dalantercept) plus axitinib. It is expected that a participant will be on this study for a variation of time (total duration will vary per subject).